A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations.

Trial Profile

A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2011

At a glance

  • Drugs Carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors NeuroDerm
  • Most Recent Events

    • 09 Nov 2011 Secondary endpoint 'Area-under-the-drug-concentration-time-curve' has been met.
    • 09 Nov 2011 Secondary endpoint 'Time-to-peak-drug-concentration' has been met.
    • 09 Nov 2011 Secondary endpoint 'Peak-drug-concentration' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top